牛牛AI助手已提取核心信息
On March 7, 2024, Novavax's President of R&D, Filip Dubovsky, completed a transaction involving the company's common stock. Dubovsky sold 9,392 shares at a price of $5.61 each, totaling $52,689.12. Prior to this sale, he exercised options to acquire 19,444 shares of Novavax common stock. Following these transactions, Dubovsky's direct holdings in Novavax amounted to 63,834 shares. The sale was executed under a transaction code indicating the payment of exercise price or tax liability by delivering or withholding securities.
On March 7, 2024, Novavax's President of R&D, Filip Dubovsky, completed a transaction involving the company's common stock. Dubovsky sold 9,392 shares at a price of $5.61 each, totaling $52,689.12. Prior to this sale, he exercised options to acquire 19,444 shares of Novavax common stock. Following these transactions, Dubovsky's direct holdings in Novavax amounted to 63,834 shares. The sale was executed under a transaction code indicating the payment of exercise price or tax liability by delivering or withholding securities.
2024年3月7日，Novavax的研发总裁菲利普·杜波夫斯基完成了一项涉及该公司普通股的交易。杜波夫斯基以每股5.61美元的价格出售了9,392股股票，总额为52,689.12美元。在此次出售之前，他行使了期权收购了19,444股Novavax普通股。这些交易之后，杜波夫斯基在Novavax的直接持股量为63,834股。此次出售是根据交易代码执行的，该交易代码表明通过交付或预扣证券来支付行使价或应纳税额。
2024年3月7日，Novavax的研发总裁菲利普·杜波夫斯基完成了一项涉及该公司普通股的交易。杜波夫斯基以每股5.61美元的价格出售了9,392股股票，总额为52,689.12美元。在此次出售之前，他行使了期权收购了19,444股Novavax普通股。这些交易之后，杜波夫斯基在Novavax的直接持股量为63,834股。此次出售是根据交易代码执行的，该交易代码表明通过交付或预扣证券来支付行使价或应纳税额。
有用
没用